DE69942742D1 - Immuntherapeutische zusammensetzung und verfahren zur behandlung von prostatakrebs - Google Patents

Immuntherapeutische zusammensetzung und verfahren zur behandlung von prostatakrebs

Info

Publication number
DE69942742D1
DE69942742D1 DE69942742T DE69942742T DE69942742D1 DE 69942742 D1 DE69942742 D1 DE 69942742D1 DE 69942742 T DE69942742 T DE 69942742T DE 69942742 T DE69942742 T DE 69942742T DE 69942742 D1 DE69942742 D1 DE 69942742D1
Authority
DE
Germany
Prior art keywords
treatment
prostate cancer
immunotherapeic
composition
prostate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69942742T
Other languages
German (de)
English (en)
Inventor
Beatrice Leveugle
Ragupathy Madiyalakan
Antoine A Noujaim
Birgit Schultes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Quest Pharmatech Inc
Original Assignee
Quest Pharmatech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quest Pharmatech Inc filed Critical Quest Pharmatech Inc
Application granted granted Critical
Publication of DE69942742D1 publication Critical patent/DE69942742D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69942742T 1998-06-15 1999-06-15 Immuntherapeutische zusammensetzung und verfahren zur behandlung von prostatakrebs Expired - Lifetime DE69942742D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8928198P 1998-06-15 1998-06-15
PCT/IB1999/001115 WO1999065523A1 (en) 1998-06-15 1999-06-15 Immunotherapeutic composition and method for the treatment of prostate cancer

Publications (1)

Publication Number Publication Date
DE69942742D1 true DE69942742D1 (de) 2010-10-21

Family

ID=22216751

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69942742T Expired - Lifetime DE69942742D1 (de) 1998-06-15 1999-06-15 Immuntherapeutische zusammensetzung und verfahren zur behandlung von prostatakrebs

Country Status (9)

Country Link
US (3) US6881405B2 (https=)
EP (1) EP1085905B1 (https=)
JP (1) JP2002518347A (https=)
AT (1) ATE480566T1 (https=)
AU (1) AU768002B2 (https=)
CA (1) CA2328504A1 (https=)
DE (1) DE69942742D1 (https=)
IL (1) IL139700A (https=)
WO (1) WO1999065523A1 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8038994B2 (en) 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
US6881405B2 (en) * 1998-06-15 2005-04-19 Altarex Medical Corp. Reagents and methods for inducing an immune response to prostate specific antigen
PL201533B1 (pl) * 1999-01-13 2009-04-30 Igeneon Krebs Immuntherapie Zastosowanie przeciwciała skierowanego przeciwko antygenowi błony komórkowej Ep-CAM
IL152748A0 (en) 2000-05-11 2003-06-24 Altarex Inc Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells
JP2005522483A (ja) * 2002-04-11 2005-07-28 アルタレックス メディカル コーポレーション 結合剤及び腫瘍細胞をターゲティングする際のそれらの使用
US20050271649A1 (en) * 2002-10-17 2005-12-08 Schultes Birgit C Therapeutic adjuvant
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
GB0329146D0 (en) * 2003-12-16 2004-01-21 Glaxosmithkline Biolog Sa Vaccine
CA2523032A1 (en) 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
US20080095790A1 (en) * 2006-10-24 2008-04-24 Perambakam Supriya M Methods of Treating Prostate Cancer
CA2700808C (en) 2007-09-27 2017-11-14 Immunovaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
EP2331130B1 (en) 2008-04-09 2018-02-14 Oncoquest Inc. Ige antibodies for the treatment of cancer
ES2524699T3 (es) * 2008-06-05 2014-12-11 Immunovaccine Technologies Inc. Composiciones que comprenden liposomas, un antígeno, un polinucleótido y un vehículo que comprende una fase continua de una sustancia hidrófoba
GB0811567D0 (en) * 2008-06-24 2008-07-30 Cytosystems Ltd Assay
EP3912643B8 (en) 2009-02-13 2023-08-23 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
EP3009455A1 (en) 2009-09-16 2016-04-20 Immunomedics Inc. Class i anti-cea antibodies and uses thereof
ES2978177T3 (es) 2009-12-02 2024-09-06 Immunomedics Inc Combinación de radio inmunoterapia y conjugados anticuerpo-fármaco para mejorar la terapia contra el cáncer
US9023802B2 (en) * 2009-12-14 2015-05-05 Immatics Biotechnologies Gmbh HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
AU2012250924B2 (en) 2011-05-02 2017-05-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
JP6240077B2 (ja) 2011-10-06 2017-11-29 イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． Ｔｌｒ２を活性化するか、またはその活性を増加させるアジュバントを含むリポソーム組成物およびその使用
AU2013302696B9 (en) 2012-08-14 2018-08-09 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
SI2900277T1 (sl) 2012-12-13 2022-05-31 Immunomedics, Inc. Odmerki imunokonjugatov protiteles in SN-38 za boljšo učinkovitost in zmanjšano toksičnost
WO2015126548A1 (en) 2014-02-21 2015-08-27 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to trop-2 expressing cells
US9139649B2 (en) 2014-02-25 2015-09-22 Immunomedics, Inc. Humanized anti-CD22 antibody
WO2015200260A1 (en) 2014-06-24 2015-12-30 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis
CN117138060A (zh) 2014-10-07 2023-12-01 免疫医疗公司 抗体-药物缀合物的新辅助剂用途
WO2016172427A1 (en) 2015-04-22 2016-10-27 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
EP4257134A3 (en) 2015-06-25 2024-01-24 Immunomedics, Inc. Combining anti-hla-dr or anti-trop-2 antibodies with microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
PL3316885T3 (pl) 2015-07-01 2021-12-06 Immunomedics, Inc. Immunokoniugaty przeciwciało-sn-38 z linkerem cl2a
US20250073349A1 (en) 2021-05-10 2025-03-06 Kawasaki Institute Of Industrial Promotion Antibody having reduced binding affinity for antigen

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3865689A (en) 1972-11-09 1975-02-11 Hoffmann La Roche Method of producing carcinoembryonic antigens
US4446122A (en) 1979-12-28 1984-05-01 Research Corporation Purified human prostate antigen
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US5053224A (en) 1983-11-07 1991-10-01 Hilary Koprowski Induction of antibody response to solid tumors with anti-idiotype antibodies
DE3650139T2 (de) 1985-07-05 1995-03-09 Hutchinson Fred Cancer Res Verfahren zum reduzieren der immunogenizität und zum induzieren immunologischer toleranz.
EP0234122A3 (en) 1986-02-21 1989-03-22 Oncogen Limited Partnership Tumor therapy with biologically active anti-tumor antibodies
AU613590B2 (en) 1986-11-19 1991-08-08 Bristol-Myers Squibb Company Hybridomas producing monoclonal antibodies to new mucin epitopes
US5059680A (en) 1986-11-24 1991-10-22 Centocor, Inc. Method of isolating ca 125 antigen
US5683674A (en) 1987-01-07 1997-11-04 Imperial Cancer Research Technology Ltd. Antibody against human mucin core protein and method of preparing and using same
US4859449A (en) 1987-09-14 1989-08-22 Center For Molecular Medicine And Immunology Modified antibodies for enhanced hepatocyte clearance
GB8728856D0 (en) 1987-12-10 1988-01-27 Bradwell A R Tumour-locating agents & method of locating tumours
EP0491867B1 (en) 1989-09-15 1996-11-27 Genetic Systems Corporation Hybridoma ct43 producing a monoclonal antibody to a mucin epitope of colorectal cancer
US5165922A (en) 1990-05-22 1992-11-24 Bristol-Myers Squibb Company Synergistic tumor therapy with combinations of biologically active anti-tumor antibodies and chemotherapy
DE4133791A1 (de) 1991-10-11 1993-04-15 Behringwerke Ag Monoklonale antikoerper gegen tumorassoziierte antigene, verfahren zu ihrer herstellung und ihre verwendung
EP0652014A1 (en) 1993-11-10 1995-05-10 National Institute Of Immunology Treatment of prostatic hypertrophy
US5773292A (en) 1995-06-05 1998-06-30 Cornell University Antibodies binding portions, and probes recognizing an antigen of prostate epithelial cells but not antigens circulating in the blood
US6143509A (en) * 1996-02-06 2000-11-07 Abbott Laboratories Prostate specific antigen peptides and uses thereof
GB9606228D0 (en) 1996-03-25 1996-05-29 Secr Defence Apparatus for matrix coating fibres with metal vapour
AU4086397A (en) 1996-09-06 1998-03-26 Centocor Inc. Monoclonal antibodies specific for prostate specific antigen and methods of detecting prostate specific antigen
US6881405B2 (en) * 1998-06-15 2005-04-19 Altarex Medical Corp. Reagents and methods for inducing an immune response to prostate specific antigen

Also Published As

Publication number Publication date
US20020136715A1 (en) 2002-09-26
ATE480566T1 (de) 2010-09-15
CA2328504A1 (en) 1999-12-23
US6881405B2 (en) 2005-04-19
AU768002B2 (en) 2003-11-27
IL139700A (en) 2005-09-25
WO1999065523A1 (en) 1999-12-23
EP1085905A1 (en) 2001-03-28
JP2002518347A (ja) 2002-06-25
US7579445B2 (en) 2009-08-25
US20090220493A1 (en) 2009-09-03
AU4159499A (en) 2000-01-05
IL139700A0 (en) 2002-02-10
EP1085905B1 (en) 2010-09-08
US20050202018A1 (en) 2005-09-15

Similar Documents

Publication Publication Date Title
DE69942742D1 (de) Immuntherapeutische zusammensetzung und verfahren zur behandlung von prostatakrebs
CY1109525T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΑ ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ErbB2 ΚΑΙ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΜΕ ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ErbB2
CY1120070T1 (el) Μεθοδοi θεραπευτικης αγωγης με τη χρηση συζευγματων αντισωματος εναντι-erbb-μεϋτανσινοειδους
DE69830072D1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
ATE208210T1 (de) Kombination von proteintyrosin-kinaseinhibitoren und chemischer kastration zur behandlung von prostatakrebs
DE60027732D1 (de) Verwendung von anti-rubeola antkörpern zur behandlung von symptomen von erkrankungen des zentralen nervensystems
DK1187632T3 (da) Behandling med anti-ErbB2-antistoffer
UA111707C2 (uk) Застосування виділеного анти-tnf-альфа антитіла людини
ATE520466T1 (de) Apparat und verfahren zur modifizierung von magnetisch inmmobilizierte biomolekulen
CY1107628T1 (el) Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων
CY1112055T1 (el) Συνθεσεις και μεθοδοι για την διαγνωση και θεραπευτικη αγωγη ογκου πνευμονα
NO20070052L (no) Fremgangsmate for behandling av multippel sklerose
ATE296839T1 (de) Antikörper zur krebsbehandlung und -diagnose
DE602004024921D1 (de) Zusammensetzungen und verfahren zur behandlung von tumoren hämatopoetischen ursprungs
BR9707819A (pt) Imunogenos peptidicos
DE60229406D1 (de) Verfahren zur behandlung oder verhinderung von vaskulärer entzündung mit sterol-absorbierungs- inhibitor(en)
ATE448775T1 (de) Rifalazil zur behandlung von infektionen mit clostridium difficile
DE69921130D1 (de) Verfahren und stoffe zur behandlung des prostatakarzinomes
DE60105025D1 (de) Pharmazeutische verbindungen zur behandlung von chronisch-obstruktiver bronchopneumonie
ATE495751T1 (de) Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper
ATE283920T1 (de) Verfahren zur immunisierung und behandlung von h. pylori infektion
ATE290881T1 (de) Verwendung von anti-ferritin antikörper bei der behandlung von bestimmten krebsarten
DE60144493D1 (de) Verfahren zur bestimmung und behandlung von tuberöse-sklerose komplex assoziierten erkrankungen
DE69930725D1 (de) Verfahren und kits zur behandlung von vulvovaginalen candidosen mit mikonazolnitrat
ATE267194T1 (de) Medikamente geeignet zur behandlung von proliferativen erkrankungen